UNION is developing orismilast, a high-potency PDE4 inhibitor targeting the PDE4B/D subtypes linked to inflammation, demonstrating potent inhibition of Th1, Th2 and Th17 pathways. It operates ...

UC is a chronic inflammatory bowel disease that causes inflammation and ulcers (sores) in the lower digestive tract with limited efficacious treatment options available Orismilast is a high-potency ...

HELLERUP, Denmark, Feb. 21, 2025 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology, today announced a ...

Before joining ImmunoGen, Ms. White served as Chief Financial Officer, Treasurer, and Principal Accounting Officer at C4 Therapeutics (NASDAQ: CCCC), where she was responsible for developing and ...

HELLERUP, Denmark, Sept. 25, 2024 /PRNewswire/ -- UNION therapeutics A/S ("UNION"), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announces ...

HELLERUP, Denmark, Sept. 20, 2024 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced ADESOS ...

HELLERUP, Denmark, Sept. 20, 2024 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced ADESOS ...

Additionally, two posters on data from the pioneering use of tape stripping for biomarker analysis in the ADESOS study and additional ADESOS Phase 2b results Orismilast is a next generation, high ...